Figure p.1

Recognized CKD & ESRD in the NHANES & Medicare populations
point prevalent patients/participants
[Download]

Figure p.2

CKD prevalence, by dataset
point prevalent patients/participants, 2006: Medicare patients age 65 & older; Medstat & Ingenix i3 patients age 20–64; NHANES participants 1999–2006, age 20 & older
[Download]


[Download]


[Download]

Figure p.3

Interaction of comorbidities, by dataset
point prevalent Medicare, Medstat, & Ingenix i3 patients, 2006; NHANES participants, 1999–2006
[Download]

Figure p.4

Adjusted hazard ratios of first hospitalization: Medicare patients
point prevalent Medicare-only patients age 66 & older, 2004
[Download]

Figure p.5

Adjusted hazard ratios of first hospitalization: Medstat patients
point prevalent Medstat patients age 50–64, 2004
[Download]


[Download]

Figure p.6

Adjusted hazard ratios of mortality: Medicare patients
point prevalent Medicare patients age 65 & older, 2004
[Download]

Figure p.7

Adjusted hazard ratios of mortality: dually-enrolled patients
point prevalent dually-enrolled patients age 65 & older, 2004
[Download]


[Download]

Figure p.8

Use of ACE inhibitors/ARBs & lipid lowering medications in CKD patients, by diabetic status: MCBS data
point prevalent MCBS patients age 65 & older
[Download]

Figure p.9

Use of ACE inhibitors/ARBs & lipid lowering medications in CKD patients, by diabetic status & age: Medstat data
point prevalent Medstat patients age 20 & older
[Download]

Figure p.10

Use of ACE inhibitors/ARBs & lipid lowering medications in CKD patients, by diabetic status & age: Ingenix i3 data
point prevalent Ingenix i3 patients age 20 & older
[Download]

Figure p.11

Per person per month inpatient/outpatient & physician/supplier costs for CKD & non-CKD patients
period prevalent patients: Medicare age 65 & older; Medstat age 50–64
[Download]